JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Eli Lilly and Co.

Închisă

SectorSănătate

795.48 0.43

Rezumat

Modificarea prețului

24h

Curent

Minim

785.34

Maxim

798.46

Indicatori cheie

By Trading Economics

Venit

-6.1B

2.8B

Vânzări

-804M

13B

P/E

Medie Sector

62.756

50.291

EPS

3.34

Randament dividend

0.79

Marjă de profit

21.678

Angajați

47,000

EBITDA

-2B

4.2B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+26.16% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.79%

2.40%

Următoarele câștiguri

6 aug. 2025

Data viitoare de dividende

10 sept. 2025

Următoarea dată ex-dividende

15 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-136B

692B

Deschiderea anterioară

795.05

Închiderea anterioară

795.48

Sentimentul știrilor

By Acuity

38%

62%

125 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Eli Lilly and Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iun. 2025, 11:56 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27 mai 2025, 14:41 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

17 iun. 2025, 14:02 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 iun. 2025, 12:12 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 iun. 2025, 11:01 UTC

Achiziții, Fuziuni, Preluări

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 iun. 2025, 10:47 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 iun. 2025, 10:47 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 iun. 2025, 10:46 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 iun. 2025, 10:45 UTC

Achiziții, Fuziuni, Preluări

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 iun. 2025, 09:33 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11 iun. 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29 mai 2025, 01:00 UTC

Top știri

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New -2-

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 mai 2025, 14:02 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 mai 2025, 14:01 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 mai 2025, 14:00 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 mai 2025, 14:00 UTC

Achiziții, Fuziuni, Preluări

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 mai 2025, 14:08 UTC

Câștiguri

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 17:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 mai 2025, 17:01 UTC

Top știri

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mai 2025, 13:56 UTC

Câștiguri

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mai 2025, 11:18 UTC

Câștiguri

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mai 2025, 09:30 UTC

Top știri

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 mai 2025, 20:30 UTC

Top știri

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 mai 2025, 04:05 UTC

Achiziții, Fuziuni, Preluări

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 mai 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 mai 2025, 14:07 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

Comparație

Modificare preț

Eli Lilly and Co. Așteptări

Obiectiv de preț

By TipRanks

26.16% sus

Prognoză pe 12 luni

Medie 999.57 USD  26.16%

Maxim 1,190 USD

Minim 700 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEli Lilly and Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

16

Cumpărare

2

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 884.54Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

125 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.